¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-2ÀÏÂ÷ : 2022-11-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-2ÀÏÂ÷ : 2022-11-11
±³À°ÀÏÀÚ : 2022-11-11
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ¿ùµå Å©¸®½ºÅ»·ë(ÇÏÀ̺긮µå Çмú´ëȸ)  
±³À°ÁÖÁ¦ : (ÇÏÀ̺긮µå)2022 KALC International Conference-2ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 110,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 07:50~08:40 How to Interpret the Results of Japan Clinical Oncology Group 0802 Study, a Comparison between Lobectomy and Segmentectomy for the Peripheral Non-Small Cell Lung Cancer  Hisao Asamura(Keio Univ., Japan) 
È޽Ġ11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 08:40~08:50 È޽Ġ () 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 08:50~09:20 Implementation of Population Based Lung Cancer Screening in Europe  John K. Field(The Univ. of Liverpool, UK) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:20~09:45 Lung Cancer Screening in Never-Smokers  Ryutaro Kakinuma(National Cancer Center, Japan) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 09:45~10:10 Functional Genomics Approaches to Understand Genetic Susceptibility to Lung Cancer  Jiyeon Choi(National Cancer Institute, USA) 
È޽Ġ11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:10~10:30 È޽Ġ () 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:30~10:50 Radiologic Characteristics of Multiple Primary Lung Cancer Including Ground Glass Nodules  Geewon Lee(Pusan National Univ) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 10:50~11:10 Pathologic Differentiation and Significance of Next-Generation Sequencing for Synchronous or Metachronous Lesions vs Metastatic or Recurred Lesions in Lung Cancer  Jin-Haeng Chung(Seoul National Univ) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:10~11:30 Surgical Strategy for Multiple Primary Lung Cancer  Alan D. L. Sihoe(Gleneagles Hong Kong Hospital, Hong Kong) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:30~11:50 Recent Advances in Radiotherapy for Multiple Primary Lung Cancer  Si Yeol Song(Univ. of Ulsan) 
È޽Ġ11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 11:50~12:00 È޽Ġ () 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 12:00~12:40 Paradigm-Leading Therapeutic Strategy for Early Stage of Lung Cancer Patients  Alan D. L. Sihoe(Gleneagles Hong Kong Hospital, Hong Kong) 
È޽Ġ11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 12:40~13:00 È޽Ġ () 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 13:00~13:40 Progress Towards Non-Small Cell Lung Cancer Models that Represent Clinical Evolutionary Trajectories  Robert E. Hynds(Univ. College London, UK) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 13:40~14:10 A Minimal Sufficient Condition for the Development of K-Ras-Activated Lung Cancer  Suk-Chul Bae(Chungbuk National Univ) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 14:10~14:40 Development of a Novel Mouse Model for Improved Evaluation of in vivo Anti-Cancer Effects: Targeted Therapy and Immunotherapy  Jin Kyung Rho(Univ. of Ulsan) 
È޽Ġ11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 14:40~15:00 È޽Ġ () 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 15:00~15:30 Clinical Application of Natural Killer T Cells to Cancer Immunotherapy  Shinichiro Motohashi(Chiba Univ., Japan) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 15:30~16:00 Natural Killer Cell-Based Cancer Immune Cell Therapy  Paul Y. Song(NKgene Biotec, USA) 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:00~16:40 Engineered Canner Immune Cell Therapy (CAR-T Cell Therapy)  Hun Ju Lee(UT MD Anderson Cancer Center,USA) 
È޽Ġ11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:40~16:50 È޽Ġ () 
±³À°½Ã°£ 11-11 ·Ôµ¥È£ÅÚ ¿ùµå Å©¸®½ºÅ»º¼·ë 16:50~17:40 The Evolving Treatment Landscape of ALK+Non-Small Cell Lung Cancer with Lorlatinib  Sehhoon Park(Sungkyunkwan Univ) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÆó¾ÏÇÐȸ (ÇÏÀ̺긮µå)2022 KALC International Conference-2ÀÏÂ÷ : 2022-11-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ (¿Â¶óÀÎ) ³­Ä¡¼ºÃµ½Ä ½ÉÆ÷Áö¾ö : 2022-11-12
´ÙÀ½±Û 2022³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦34Â÷ Ãß°èÇмú´ëȸ(1ÀÏÂ÷) : 2022-11-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21105 ¼­¿ï Á¦34Â÷ ÀÏÂ÷ÀÇ·áÀÎÀ» À§ÇÑ ³»½Ã°æ ¿¬¼ö°­Á : 2024-07-07 0 10 2024-06-19
21104 ºÎ»ê Á¦6±â ºÎ»ê±¤¿ª½ÃÀÇ»çȸ ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤ : 2024-07-07 0 14 2024-06-19
21103 ´ë±¸ ´ë±¸°æºÏ³»°úÀÇ»çȸ ÇÏ°èÇмú´ëȸ : 2024-07-07 0 9 2024-06-19
21102 ¼­¿ï Á¦17ȸ ¼¼ºê¶õ½º ¾î¸°À̺´¿ø ¼Ò¾Æû¼Ò³âÁúȯ ½ÉÆ÷Áö¾ö : 2024-07-07 0 10 2024-06-19
21101 ¼­¿ï Á¦13ȸ ÁßÀå³â ¿©¼º°Ç°­ ¿¬¼ö°­Á : 2024-06-30 0 4 2024-06-18
21100 ¼­¿ï ´ëÇÑ°¡Àӷº¸Á¸ÇÐȸ Á¦21Â÷ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-06-30 0 7 2024-06-18
21099 ¼­¿ï Á¦ 3ȸ ´ëÇѼҾÆû¼Ò³âÇൿ¹ß´ÞÁõÁø Çмú´ëȸ : 2024-06-30 0 15 2024-06-18
21098 ¼­¿ï 2024 ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-07 0 11 2024-06-19
21097 ´ëÀü Á¦ 19Â÷ ´ëÀüÃæûÁöȸ Åõ¼®½ÉÆ÷Áö¾ö : 2024-07-07 0 12 2024-06-19
21096 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú Á¦22ȸ ¿À°ø ½ÉÆ÷Áö¾ö : 2024-07-07 0 5 2024-06-19
21095 ºÎ»ê Á¦ 9Â÷ ´ëÇÑ»êºÎÀΰúÃÊÀ½ÆÄÇÐȸ ºÎ»ê°æ³²Áöȸ ¿¬¼ö°­Á : 2024-07-07 0 12 2024-06-19
21094 ¼­¿ï Á¦ 2ȸ ´ëÇѼҾƽŰæ¹ß´ÞÇൿ¿¬±¸È¸ Çмú½ÉÆ÷Áö¾ö : 2024-07-07 0 6 2024-06-19
21093 ºÎ»ê (ÇÏÀ̺긮µå) ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ºÎ»ê,¿ï»ê,°æ³²Áöȸ - Á¦2ȸ ¿¬¼ö°­Á : 2024-07-07 0 12 2024-06-19
21092 ¼­¿ï ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ 2024³â ÆÀÇÇÁö¼Ç ½Ç½À °úÁ¤ Part¥° : 2024-07-07 0 4 2024-06-19
21091 ±¤ÁÖ 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ±¤ÁÖÀü³²Áöȸ ¿¬¼ö°­Á : 2024-07-07 0 6 2024-06-19
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷